C-Peptide ELISA Kit (DEIA2234)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma, urine
Species Reactivity
Human
Intended Use
The C-Peptide ELISA is an enzyme immunoassay for the quantitative measurement of C peptide in serum, plasma and urine.
Contents of Kit
1. Microtiter wells, 12 x 8 (break apart) strips, 96 wells
2. Standard (Standard 0-5), 6 vials, lyophilized, 0.75 mL
3. Sample Diluent, 1 vial, 3 mL
4. Antiserum, 1 vial, 7 mL
5. Enzyme Conjugate, 1 vial, 14 mL
6. Enzyme Complex, 1 vial, 14ml
7. Substrate Solution, 1 vial, 14 mL
8. Stop Solution, 1 vial, 14 mL
9. Wash Solution, 1 vial, 30 mL (40X concentrated)
Storage
When stored at 2-8°C unopened reagents will retain reactivity until expiration date. For more detailed information, please download the following document on our website.
Detection Range
0.06-16 ng/mL
Sensitivity
0.064 ng/mL

Citations


Have you cited DEIA2234 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Efficient Selection Scheme for Incorporating Noncanonical Amino Acids Into Proteins inSaccharomyces cerevisiae

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY

Authors: Tan, Linzhi; Zheng, Zhaohui; Xu, Yuanwei; Kong, Weikaixin; Dai, Zhen; Qin, Xuewen; Liu, Tao; Tang, Hongting

With the advances in the field of expanded genetic code, the application of non-canonical amino acid (ncAA) is considered an effective strategy for protein engineering. However, cumbersome and complicated selection schemes limit the extensive application of this technology inSaccharomyces cerevisiae. To address this issue, a simplified selection scheme with confident results was developed and tested in this study. Based on a mutation library derived fromEscherichia colityrosyl-tRNA synthetase (EcTyrRS), a logic gate in synthetic biology was used to optimize screening procedures. We found that an "and" gate was more suitable than an "or" gate for isolating aminoacyl-tRNA synthetase fromS. cerevisiae. The successful incorporation ofO-methyltyrosine (OMeY) proved the utility and efficiency of this new selection scheme. After a round of positive selection, several new OMeY-tRNA synthetase (OMeYRS) mutants were screened, and their incorporation efficiency was improved. Furthermore, we characterized the insertion of several tyrosine analogs into Herceptine Fab and discovered that OMeYRS and its mutants were polyspecific. One of these mutants showed an optimal performance to incorporate different ncAAs into recombinant proteins inS. cerevisiae; this mutant was cloned and transfected into mammalian cells, and the results proved its functionality in HEK293 cells. This study could expand the application of ncAA inS. cerevisiaeto construct efficient yeast cell factories for producing natural and synthetic products.

Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Authors: Al-Sheikh, Abrar; Yousef, Al-Motassem; Alshamaseen, Daniah; Farhad, Rand

Background High-dose methotrexate (HD- MTX) is the cornerstone of chemotherapy for acute lymphoblastic leukemia (ALL), and one of its target enzymes is Thymidylate Synthase (TYMS). We hypothesized that genetic polymorphisms of TYMS gene would be associated with MTX toxicity in ALL children. Methods 64 children with ALL were included in this study. Genotyping analysis was conducted on three common polymorphisms: tandem repeats in the promoter-enhancer region (VNTR), 6 bp ins/del (1494del6) in the 5 ' UTR, and rs2790 A > G in the 3 '-untranslated region (3 '-UTR). The association between genetic polymorphisms and MTX toxicity was studied. Results Genetic polymorphism of TYMS was associated with hematological toxicities but not with non-hematological adverse events. A significant association between TYMS 1494del6 genotypes and incidence of neutropenia (ANC < 1700 mm(3)), infection and leukopenia was observed. Carriers of the dominant allele (Del) were 6 times more likely to develop neutropenia compared to minor genotype carriers (OR (95% CI) 6 (1.2-31.1); p = 0.04), and 4.2 times less likely to have infection, as compared to Ins/Ins carriers (OR 4.2, 95% CI (1.1-16); p = 0.04). Carriers of Del allele were 9.2 times more likely to develop grade 3 and 4 leukopenia, p = 0.02, 95% CI (1.1-75.6). Significant association was found between 28 bp VNTR and thrombocytopenia; (OR 3.3, 95% CI (1.1-10), p = 0.04). No significant association was found between TYMS rs2790 A > G genetic polymorphisms and MTX hematologic toxicities. Conclusion Genetic polymorphism of TYMS1494del6 may modulate susceptibility to MTX toxicity.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket